# A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)

> **NCT01101464** · PHASE2 · COMPLETED · sponsor: **Organon and Co** · enrollment: 8 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Asenapine 3x5mg followed by 1x15mg
- **DRUG:** Asenapine 1x15mg followed by 3x5mg

## Key facts

- **NCT ID:** NCT01101464
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2002-12
- **Final completion:** 2002-12
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2022-02-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01101464

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01101464, "A Trial to Determine Whether Two Differing Strength Tablets (3 x 5 mg Versus 1 x 15 mg) of Sublingually Org 5222 (Asenapine) Are Safe and Equal in Subjects With Schizophrenia or Schizoaffective Disorder (P05937)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01101464. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*